Pediatric flu vaccine data
Executive Summary
Influenza strain data and vaccine response research for pediatric populations "has not really gotten the priority...it deserves" due to limited resources, Office of Vaccines Research & Review Supervisory Medical Officer Roland Levandowski, MD, tells agency's vaccines advisory committee. In January 2002, committee "strongly recommended" that strain surveillance data be obtained from a pediatric population to study immunogenicity and efficacy of the vaccine. At Feb. 20 meeting on strain selection, several committee members cited a pressing need for pediatric data in light of recommendations for increased flu vaccine use in children (1"The Pink Sheet" July 8, 2002, p. 12)...
You may also be interested in...
Pediatric Flu Vaccine Formulation Should Be Developed, Advisory Cmte. Says
A pediatric flu vaccine containing two influenza B strains should be developed, members of the FDA's Vaccines & Related Biological Products Advisory Committee recommended
Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually
Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually
Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: